Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19

Affiliations

• ¹ Department of Dermatology and Allergy, University of Bonn, Bonn, Germany.
• ² Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland.
• ³ Department of Rheumatology, Helios Clinic Vogelsang-Gommern, Cooperation Partner of the Otto-Von-Guericke University, Sophie-von-Boetticher-Straße 1, Vogelsang-Gommern, 39245, Germany.
• ⁴ Clinical Medicine, Trinity College Dublin, Dublin, Ireland.
• ⁵ Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
• ⁶ Eli Lilly and Company, Indianapolis, IN, USA.
• ⁷ The Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road, Oxford, OX3 7LD, UK. peter.taylor@kennedy.ox.ac.uk.